Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr 10;1(1):ofu006.
doi: 10.1093/ofid/ofu006. eCollection 2014 Mar.

Empiric vancomycin use in febrile neutropenic oncology patients

Affiliations

Empiric vancomycin use in febrile neutropenic oncology patients

Jessica Libuit et al. Open Forum Infect Dis. .

Abstract

Vancomycin is commonly added as empiric therapy for febrile neutropenia. A retrospective chart review was conducted at a large community teaching institution to evaluate vancomycin use in oncology patients. The results revealed that a majority of empiric vancomycin therapy was inappropriate, raising concern for antibiotic resistance and prompting opportunities for improvement.

Keywords: antibiotics; empiric; febrile neutropenia; oncology; vancomycin.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Moellering RC., Jr. Vancomycin: a 50-year reassessment. Clin Infect Dis. 2006;42(Suppl 1):S3–4. - PubMed
    1. Paul M, Borok S, Fraser A, et al. Empirical antibiotics against gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2005;55:436–44. - PubMed
    1. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56–93. - PubMed
    1. Wright JD, Neugut AI, Anath CV, et al. Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes. JAMA Intern Med. 2013;173:559–68. - PMC - PubMed
    1. Dellinger PR, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39:165–228. - PMC - PubMed